Effect of moxonidine on parameters of lipid metabolism in patients with metabolic syndrome

被引：0
|
作者：
Anichkov, DA [1 ]
Shostak, NA [1 ]
机构：
[1] Russian State Med Univ, Moscow 117437, Russia
来源：
KARDIOLOGIYA | 2004年 / 44卷 / 09期
关键词：
metabolic syndrome; lipid metabolism; moxonidine;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aim. To compare effects of moxonidine and lisinopril on parameters of lipid metabolism in patients with metabolic syndrome. Methods. Moxonidine (0.2-04 mg/day) and lisinopril (10-20 mg/day) were given to 25 and 24 patients, respectively. Blood pressure, heart rate, parameters of lipid profile and fasting blood glucose were measured before and after 12 weeks of treatment. Results. Antihypertensive efficacy of 2 drugs was similar. No changes of lipid profile occurred in lisinopril treated patients while significant elevation of high density lipoprotein cholesterol and tendency to lowering of triglyceride level were observed in moxonidine group. Conclusion. Therapy with moxonidine was associated with favorable changes of lipid profile.
引用
收藏
页码：13 / 15
页数：3
相关论文
共 50 条
  • [1] The effect of moxonidine on endothelial dysfunction in metabolic syndrome
    Topal E.
    Cikim A.S.
    Cikim K.
    Temel I.
    Ozdemir R.
    American Journal of Cardiovascular Drugs, 2006, 6 (5) : 343 - 348
  • [2] Use of moxonidine in antihypertensive treatment of patients with overweight and/or metabolic syndrome
    Marsalek, P
    Wagner, T
    Sharma, AM
    PERFUSION, 2003, 16 (04): : 153 - 160
  • [3] Pecularities of Prolonged Use of Moxonidine in Patients with Hypertension Associated with Metabolic Syndrome
    S. I. Kseneva
    E. V. Borodulina
    T. A. Semiglazova
    N. V. Kulakova
    I. V. Tarasova
    O. Ju. Trifonova
    T. D. Gridneva
    V. V. Udut
    Bulletin of Experimental Biology and Medicine, 2011, 151
  • [4] Moxonidine-based combination antihypertensive therapy in patients with metabolic syndrome
    Tishina, E., V
    Mychka, V. B.
    Saidova, M. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2012, 11 (03): : 36 - 46
  • [5] Effect of moxonidine on lipid subfractions in patients with hypertension
    Lumb, PJ
    McMahon, Z
    Chik, G
    Wierzbicki, AS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (05) : 465 - 468
  • [6] Pecularities of Prolonged Use of Moxonidine in Patients with Hypertension Associated with Metabolic Syndrome
    Kseneva, S. I.
    Borodulina, E. V.
    Semiglazova, T. A.
    Kulakova, N. V.
    Tarasova, I. V.
    Trifonova, O. Ju.
    Gridneva, T. D.
    Udut, V. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2011, 151 (04) : 400 - 404
  • [7] The effect of carvedilol on metabolic parameters in patients with metabolic syndrome
    Uzunlulu, Mchmet
    Oguz, Aytekin
    Yorulmaz, Elif
    INTERNATIONAL HEART JOURNAL, 2006, 47 (03) : 421 - 430
  • [8] Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study
    Sharma, AM
    Wagner, T
    Marsalek, P
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (09) : 669 - 675
  • [9] Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study
    A M Sharma
    T Wagner
    P Marsalek
    Journal of Human Hypertension, 2004, 18 : 669 - 675
  • [10] Possibilities of the Use of Moxonidine in the Treatment of Arterial Hypertension in Patients With Metabolic Syndrome and Diabetes
    Minushkina, L. O.
    KARDIOLOGIYA, 2011, 51 (04) : 74 - 78
12345